Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radium-223 + Enzalutamide vs Enzalutamide in mCRPC
NCT02199197Phase 2Completed
- Sponsor
- University of Utah
- Start
- Jun 2014
- Primary completion
- Apr 2018
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
A Phase 2 trial of radium-223 dichloride in metastatic castration-resistant prostate cancer (mCRPC), sponsored by University of Utah. Started Jun 2014; status: completed.
02
Drugs
radium-223 dichloride
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02199197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02199197.